Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum

Sunday, July 27, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study presented at the 2025 Alzheimer’s Association International Conference highlights the benefits of Zervimesine (CT1812) for patients with mild-to-moderate Alzheimer's disease. The treatment particularly aids those with lower baseline plasma p-tau217 levels. This research contributes to the growing understanding of Alzheimer's therapies.
Price reaction · baseline $0.84 (2025-07-25 close) · 5 other CGTX headline(s) in the window, move may be shared
day 0 close
-14.9%
day 1
-20.2%
day 3 · peak
-30.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zervimesine shows promise in treating mild-to-moderate Alzheimer's disease.
  • Benefits observed in patients with lower baseline plasma p-tau217.
  • Research presented at a prominent Alzheimer's conference.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Grundman M, Catalano S, Hamby ME, et al. Zervimesine (CT1812) Treatment Benefits Patients with Lower Baseline Plasma p-tau217 Across the Mild-to-Moderate AD Spectrum . Poster presented at 2025 Alzheimer’s Association International Conference (AAIC) ; Toronto, Ontario, Canada

Frequently Asked Questions

What is Zervimesine (CT1812)?

Zervimesine (CT1812) is a treatment investigated for its benefits in Alzheimer's disease.

What patient group benefits from Zervimesine?

Patients with mild-to-moderate Alzheimer's and lower baseline plasma p-tau217 benefit.

Where was the research on Zervimesine presented?

The research was presented at the 2025 Alzheimer’s Association International Conference.

What condition does Zervimesine target?

Zervimesine targets mild-to-moderate Alzheimer's disease.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare Zervimesine CT1812 Alzheimer's disease p-tau217 clinical trial
Last updated: Jul 27, 2025

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →